Binimetinib + Belinostat
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma
Trial Timeline
Dec 15, 2021 → Jan 1, 2028
NCT ID
NCT05170334About Binimetinib + Belinostat
Binimetinib + Belinostat is a phase 2 stage product being developed by Pfizer for Metastatic Uveal Melanoma. The current trial status is active. This product is registered under clinical trial identifier NCT05170334. Target conditions include Metastatic Uveal Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Uveal Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05170334 | Phase 2 | Active |
Competing Products
20 competing products in Metastatic Uveal Melanoma